Sophie Cousin, MD, Institut Bergonié, Bordeaux, France, highlights the significance of finding a reliable biomarker to predict patient outcomes for early phase trials selection. Currently, there is a lack of good biomarkers available for this purpose. However, tumor fraction, which can be measured through liquid biopsies, offers a promising solution. By assessing tumor fraction, researchers can gain insights into patient survival rates prior to proposing early phase trials. This makes tumor fraction an intriguing and valuable biomarker with the potential to enhance patient selection and improve the precision of oncology trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
